Zynerba Pharmace Stock Price, News & Analysis

Zynerba Pharmaceuticals (NASDAQ: ZYNE) recently presented promising results from the Phase 2 BELIEVE trial at the 2020 American Epilepsy Society meeting. The data showed a median 73% reduction in monthly seizure frequency after 12 months of Zygel treatment in children with developmental and epileptic encephalopathies (DEE). The trial also highlighted Zygel's positive impact on sleep disturbances, with significant improvements reported across various sleep issues. The results underscore Zygel's potential as a well-tolerated treatment in a challenging patient population, warranting further investigation.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced the acceptance and presentation of two posters at the 2020 virtual annual meeting of the American Epilepsy Society, taking place from December 4-8, 2020. The posters will detail findings from the BELIEVE clinical trial of ZYN002, a transdermal cannabinoid gel, focused on children and adolescents with developmental and epileptic encephalopathies. The presentations are scheduled for December 4, 2020, and will be accessible on Zynerba's website post-presentation.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported third-quarter results for 2020, highlighting significant clinical progress, especially in its Zygel treatments for Fragile X Syndrome (FXS) and Autism Spectrum Disorder (ASD). Key findings from the CONNECT-FX trial indicated that over 58% of patients showed clinically meaningful improvement in socially avoidant behavior. The company also received a new U.S. patent for cannabidiol treatment of FXS. Financially, Zynerba ended the quarter with $64.3 million in cash, reporting a net loss of $9 million. Management anticipates sufficient funding until late Q4 2021.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) presented data from the CONNECT-FX trial at the virtual Joint 16th International Child Neurology Congress and the AACAP 2020 Annual Meeting. The study investigated the role of FMR1 methylation status in children with Fragile X syndrome (FXS) as it relates to disease severity and treatment response to Zygel (ZYN002). The results indicate that patients with fully methylated FMR1 achieved significant improvements in behavioral symptoms compared to placebo, including statistically significant changes in social avoidance and irritability. FDA discussions are planned for Q4 2020.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) presented new data from the Phase 2 BRIGHT trial indicating that Zygel (ZYN002) may improve core behavioral symptoms in children and adolescents with Autism Spectrum Disorder (ASD) when added to standard care. The trial enrolled patients aged 3 to <18 years and showed statistically significant caregiver-reported improvements across all Autism Impact Measure subscales, with notable results in Communication (p<0.001) and Social Reciprocity (p=0.0053). The findings were shared at the virtual Joint 16th International Child Neurology Congress and the upcoming AACAP 2020 Annual Meeting.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) recently presented data from the Phase 2 BRIGHT trial for Zygel™, a transdermal gel for treating children and adolescents with Autism Spectrum Disorder (ASD). Initial findings suggest Zygel may improve core behavioral symptoms when combined with standard care. Key improvements in caregiver-reported outcomes across all Autism Impact Measure subscales were statistically significant. The trial evaluated safety, tolerability, and efficacy over 14 weeks, with results indicating a positive benefit-risk profile. Future controlled trials are anticipated to validate these findings.

Zynerba Pharmaceuticals (NASDAQ: ZYNE) announced the acceptance of two oral presentations at the virtual AACAP 2020 Annual Meeting occurring from October 12-24, 2020. The presentations will focus on clinical trial responses to Zygel in children and adolescents with Fragile X syndrome and autism spectrum disorder. Dr. Joseph Palumbo expressed gratitude for the opportunity to share significant findings with the scientific community. The oral presentations are scheduled for October 23, 2020, and will discuss the role of methylation status and the efficacy of ZYN002 Cannabidiol transdermal gel.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced the acceptance of two posters for the virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) from October 12-23, 2020. The posters focus on ZYN002, a transdermal cannabidiol gel, addressing its role in Fragile X Syndrome and its efficacy in Autism Spectrum Disorder. The data aims to explore disease severity and treatment tolerability in children and adolescents. Full posters will be available on the company's website during the event.

Zynerba Pharmaceuticals (NASDAQ: ZYNE) has received orphan drug designation from the FDA for its cannabidiol (CBD) gel, Zygel™, intended to treat 22q11.2 deletion syndrome (22q), a rare condition affecting 81,000 individuals in the U.S. The designation may provide tax incentives, fee waivers, and a seven-year exclusive marketing period. CEO Armando Anido emphasized the urgency in developing therapeutics for this patient group. 22q syndrome is associated with significant neuropsychiatric and behavioral challenges, including anxiety and social interaction difficulties.